

Jing An

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9031622/publications.pdf>

Version: 2024-02-01

38
papers

671
citations

759233

12
h-index

580821

25
g-index

38
all docs

38
docs citations

38
times ranked

1096
citing authors

#	ARTICLE	IF	CITATIONS
1	Exploring the Stereochemistry of CXCR4-Peptide Recognition and Inhibiting HIV-1 Entry with d-Peptides Derived from Chemokines. <i>Journal of Biological Chemistry</i> , 2002, 277, 17476-17485.	3.4	109
2	Drug Discovery Research Targeting the CXC Chemokine Receptor 4 (CXCR4). <i>Journal of Medicinal Chemistry</i> , 2012, 55, 977-994.	6.4	102
3	Discovery of small molecule inhibitors of the Wnt/ β -catenin signaling pathway by targeting β -catenin/Tcf4 interactions. <i>Experimental Biology and Medicine</i> , 2017, 242, 1185-1197.	2.4	65
4	Targeting Chemokine Receptor CXCR4 for Treatment of HIV-1 Infection, Tumor Progression, and Metastasis. <i>Current Topics in Medicinal Chemistry</i> , 2014, 14, 1574-1589.	2.1	45
5	A Novel Synthetic Bivalent Ligand To Probe Chemokine Receptor CXCR4 Dimerization and Inhibit HIV-1 Entry. <i>Biochemistry</i> , 2012, 51, 7078-7086.	2.5	33
6	SMM-Chemokines: A Class of Unnatural Synthetic Molecules as Chemical Probes of Chemokine Receptor Biology and Leads for Therapeutic Development. <i>Chemistry and Biology</i> , 2006, 13, 69-79.	6.0	30
7	A synthetic bivalent ligand of CXCR4 inhibits HIV infection. <i>Biochemical and Biophysical Research Communications</i> , 2013, 435, 646-650.	2.1	30
8	The chemical biology of apoptosis: Revisited after 17 years. <i>European Journal of Medicinal Chemistry</i> , 2019, 177, 63-75.	5.5	26
9	Niclosamide inhibits ovarian carcinoma growth by interrupting cellular bioenergetics. <i>Journal of Cancer</i> , 2020, 11, 3454-3466.	2.5	21
10	Crystal Structure and Structural Mechanism of a Novel Anti-Human Immunodeficiency Virus and α -Amino Acid-Containing Chemokine. <i>Journal of Virology</i> , 2007, 81, 11489-11498.	3.4	20
11	Enhancement of Radiation Sensitivity in Lung Cancer Cells by a Novel Small Molecule Inhibitor That Targets the β -Catenin/Tcf4 Interaction. <i>PLoS ONE</i> , 2016, 11, e0152407.	2.5	19
12	LAIR-1 suppresses cell growth of ovarian cancer cell via the PI3K-AKT-mTOR pathway. <i>Aging</i> , 2020, 12, 16142-16154.	3.1	16
13	A new class of α -ketoamide derivatives with potent anticancer and anti-SARS-CoV-2 activities. <i>European Journal of Medicinal Chemistry</i> , 2021, 215, 113267.	5.5	13
14	Design, synthesis, and biological characterization of novel PEG-linked dimeric modulators for CXCR4. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 5393-5399.	3.0	12
15	Chemical mutagenesis of a GPCR ligand: Detoxifying α -inflammo-attraction to direct therapeutic stem cell migration. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 31177-31188.	7.1	10
16	Design, synthesis and characterization of potent microtubule inhibitors with dual anti-proliferative and anti-angiogenic activities. <i>European Journal of Medicinal Chemistry</i> , 2018, 157, 380-396.	5.5	9
17	Design, synthesis, and biological characterization of a new class of symmetrical polyamine-based small molecule CXCR4 antagonists. <i>European Journal of Medicinal Chemistry</i> , 2020, 200, 112410.	5.5	9
18	Discoveries and developments of CXCR4-targeted HIV-1 entry inhibitors. <i>Experimental Biology and Medicine</i> , 2020, 245, 477-485.	2.4	9

#	ARTICLE	IF	CITATIONS
19	Five ETS family members, ELF-1, ETV-4, ETV-3L, ETS-1, and ETS-2 upregulate human leukocyte-associated immunoglobulin-like receptor-1 gene basic promoter activity. <i>Aging</i> , 2018, 10, 1390-1401.	3.1	9
20	Convenient Synthesis of Toxoflavin that Targets β -Catenin/Tcf4 Signaling Activities. <i>Journal of Heterocyclic Chemistry</i> , 2014, 51, 594-597.	2.6	8
21	Discovery and Computational Analyses of Novel Small Molecule Zika Virus Inhibitors. <i>Molecules</i> , 2019, 24, 1465.	3.8	8
22	High affinity CXCR4 inhibitors generated by linking low affinity peptides. <i>European Journal of Medicinal Chemistry</i> , 2019, 172, 174-185.	5.5	8
23	Virtual Screening, Biological Evaluation, and 3D-QSAR Studies of New HIV-1 Entry Inhibitors That Function via the CD4 Primary Receptor. <i>Molecules</i> , 2018, 23, 3036.	3.8	7
24	A novel dimeric CXCR4 antagonist synergizes with chemotherapy in acute myeloid leukaemia by mobilizing leukaemic cells from their associated bone marrow niches. <i>British Journal of Haematology</i> , 2019, 187, e11-e15.	2.5	7
25	Bivalent Ligand Aiming Putative Mu Opioid Receptor and Chemokine Receptor CXCR4 Dimers in Opioid Enhanced HIV-1 Entry. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 2318-2324.	2.8	7
26	Design and synthesis of a bivalent probe targeting the putative mu opioid receptor and chemokine receptor CXCR4 heterodimer. <i>RSC Medicinal Chemistry</i> , 2020, 11, 125-131.	3.9	6
27	Three dimensional <i>de novo</i> micro bone marrow and its versatile application in drug screening and regenerative medicine. <i>Experimental Biology and Medicine</i> , 2015, 240, 1029-1038.	2.4	5
28	Structural and Biological Characterizations of Novel High-Affinity Fluorescent Probes with Overlapped and Distinctive Binding Regions on CXCR4. <i>Molecules</i> , 2019, 24, 2928.	3.8	5
29	Trends in application of advancing computational approaches in GPCR ligand discovery. <i>Experimental Biology and Medicine</i> , 2021, 246, 1011-1024.	2.4	5
30	A novel small molecule CXCR4 antagonist potently mobilizes hematopoietic stem cells in mice and monkeys. <i>Stem Cell Research and Therapy</i> , 2021, 12, 17.	5.5	4
31	Biomodification of PCL Scaffolds with Matrigel, HA, and SR1 Enhances <i>De Novo</i> Ectopic Bone Marrow Formation Induced by rhBMP-2. <i>BioResearch Open Access</i> , 2015, 4, 298-306.	2.6	3
32	LC-MS/MS assay for the determination of a novel D-peptide antagonist of CXCR4 in rat plasma and its application to a preclinical pharmacokinetic study. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 161, 159-167.	2.8	3
33	A fragment integrational approach to GPCR inhibition: Identification of a high affinity small molecule CXCR4 antagonist. <i>European Journal of Medicinal Chemistry</i> , 2022, 231, 114150.	5.5	3
34	Pharmacokinetics of a novel microtubule inhibitor mHA11 in rats. <i>Chemico-Biological Interactions</i> , 2019, 308, 235-243.	4.0	2
35	Hyperosmotic intraventricular drug delivery of DV1 in the management of intracranial metastatic breast cancer in a mouse model. <i>Journal of Clinical Neuroscience</i> , 2019, 62, 207-211.	1.5	2
36	Difficult to evaluate the effect of remimazolam. <i>Journal of Anesthesia</i> , 2022, , 1.	1.7	1

#	ARTICLE	IF	CITATIONS
37	A case of mesenchymal hamartoma of the chest wall in neonates. Asian Journal of Surgery, 2022, , .	0.4	0
38	A giant rhabdomyosarcoma of the neck in neonates. Asian Journal of Surgery, 2022, , .	0.4	0